目前还没有真实世界研究调查过GLP-1RA与基础胰岛素相比,在接受主流SGLT2i 治疗的 T2D 和 CKD成人患者中的疗效。 2024年8月《Diabetes Obes Metab》杂志发表了一项来自加拿大的真实世界研究,目的是比较对于已经接受 SGLT2i 治疗且未达到血糖控制目标的 T2D 和 CKD 患者启动GLP-1 RA 与启动基础胰岛素的有效性。 该...
Glycemic control is capable of modestly slowing the development of diabetic peripheral neuropathy and CV autonomic neuropathy in patients with T2D, but cannot reverse the loss of neurons. Other than glycemic control, there are no specific treatments available for underlying nerve damage. However...
There is limited real-world data evaluating outcomes of glucagon-like peptide-1 receptor agonists (GLP1-RA) use in patients with moderate to advanced CKD. Here, emulating a clinical trial, the authors show that GLP1-RA use in patients with CKD is associated with lower rate of acute healthca...
Metformin is well studied and has the longest history of safety for the prevention of diabetes and is recommended by ADA for patients at high risk of T2D; however, in terms of the chances of reducing the risk of diabetes, it is not as effective as liraglutide, semaglutide or TZDs, although...
Less commonly used antihypertensive treatments include α-blockers, renin inhibitors, loop diuretics, substances affecting the central nervous system such as methyl- dopa or clonidine, and drugs that directly lower the tension of vascular smooth muscle, for instance dihydralazine. The exact choice of ...
Diabetes Dialogue: Understanding Semaglutide (Ozempic) in CKD and T2D January 31st 2025 In this episode, hosts discuss the approval of semaglutide (Ozempic) for reducing the progression of kidney disease in type 2 diabetes. Diabetes Dialogue: ADA’s 2025 Standards of Care in Diabetes Therapeutics ...
≥ 5 years; concomitant CKD (-) vs. (+); and multiple antidiabetic combination treatments with < 3 classes vs. ≥ 3 classes. Cox regression analysis was conducted as the primary analysis after adjustment for potential confounders. Statistical analyses were performed using the SAS software ...
To ensure efficient resource allocation, given the wide range of treatments for patients with CKD associated with T2D and the relatively significant healthcare expenditure, it is important to assess the cost-effectiveness of new treatments. Recently, the FINE-CKD model has been validated for estimatin...
Ozempic Approval Expanded to Include Patients with T2D and CKD: Daily Dose Sydney Jennings February 13th 2025 Your daily dose of the clinical news you may have missed. Diabetes Caution: FDA Warns of Risk of Missing Critical Alerts from Smartphone-Compatible Diabetes Devices Grace Halsey February ...
Although guideline-directed medical therapy (GDMT) is an evidence-based, proven approach to manage chronic kidney disease and type 2 diabetes (CKD + T2DM), adherence is low and multifactorial. Opportunities exist to improve care delivery, thus delaying disease progression, avoiding unnecessary costs,...